Feb 24, 2021 | News, Regulatory
Sinopharm, a unit of the China National Pharmaceutical Group, and CanSinoBiologics Inc both have applied in China for the public use of their COVID-19 vaccines. Currently, China has two approved vaccines that were developed within the country, and has yet to approve... 
Feb 10, 2021 | News, Regulatory
Pfizer announced that it was withdrawing its application for emergency use authorization (EUA) in India for its COVID-19 vaccine. The pharmaceutical company failed to meet India’s regulatory requirements for a local immunogenicity study to ensure the safety of the... 
Dec 28, 2020 | News, Regulatory
The Chinese company InnoCare Pharma announced today (12/28) that its BTK inhibitor orelabrutinib received approval for the treatment of cancer and autoimmune diseases, specifically relapsed/refractory chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma... 
Dec 3, 2020 | Medical Translation
In the face of global issues in the life sciences sector, cross-border communication and collaboration are more important than ever. To address this need, CSOFT co-organized the GBA-Health 2020 Panel Discussion on cross border opportunities and challenges in the life... 
Oct 8, 2020 | News, Regulatory
A United Arab Emirates company, Group42 or G42, is nearing the end of phase 3 clinical trials for a Chinese COVID-19 vaccine. They are hoping to start producing in the masses next year. This potential vaccine was a product of the partnership between G42, an Abu-Dhabi...
